Key Highlights

  • Creo Medical Group Plc (LSE:CREO) shares rose 3.11% on 5 October 2026 following recent interim results.
  • First-half 2026 Revenue increased 45% to £3.2 million, while the underlying operating loss narrowed by more than 25% to £4.9 million.
  • Management expects full-year revenue growth of 50% to 60%, supported by a strong order book and a typically second-half-weighted profile.
  • Cash was £7.4 million at the end of June 2026, backed by a £5.5 million placing and a £2.0 million convertible Loan note from the Development Bank of Wales.
  • The planned sale of Creo's remaining 49% stake in Creo Medical Europe is expected to further strengthen the balance sheet.

Why Creo Medical Shares Moved Higher on 5 October 2026

Creo Medical Group Plc (LSE:CREO) gained 3.11% on 5 October 2026, as investors continued to digest interim results published in late September. The shares had traded near 11.88p at the end of September, well below the 15p placing price set in May 2026, and some investors view that discount as an opportunity given the company's improving fundamentals.

Strong Revenue Growth

Creo, based in Chepstow, Wales, develops minimally invasive electrosurgical devices that bring advanced energy to endoscopy, helping clinicians treat pre-cancerous and cancerous lesions without major surgery. Revenue for the first half of 2026 rose 45% to £3.2 million from £2.2 million, in line with management expectations. Growth was driven by increased adoption of its advanced energy platform, broader clinician engagement and expansion into new regions.

Losses Narrowing as Costs Fall

The underlying operating loss narrowed by more than 25% to £4.9 million, reflecting disciplined cost control and a simplified operating model. In April 2026 Creo announced the disposal and outsourcing of its Manufacturing operations, which completed in the second quarter and supports a more scalable model. Chief Executive Craig Gulliford has framed these steps as central to the group's path toward profitability.

Funding and the CME Stake Sale

In May 2026 Creo completed an Equity placing raising about £5.5 million and established a £2.0 million convertible loan note subscribed by the Development Bank of Wales. Cash stood at £7.4 million at the end of June. The company is also selling its remaining 49% stake in Creo Medical Europe to a company owned by that business's chief executive, at an indicative value in line with its carrying value, with payment expected in cash. Completion was expected during the third quarter. Creo Medical Europe will remain a distributor of Creo's products in key European markets.

Full-Year Guidance

Creo expects full-year revenue growth of 50% to 60%, supported by a strong order book carried into the second half and its usual seasonality. Growing external clinical validation and presentations by key opinion leaders are helping to drive adoption.

Why Investors Are Watching LSE:CREO

Investors are watching Creo Medical because it offers exposure to the growing field of surgical endoscopy, a market driven by the push toward less invasive, lower-cost procedures. Analyst price targets sit well above the current share price, and confirmation of the CME stake proceeds plus delivery of full-year growth guidance could act as catalysts.

Risks to Consider

Creo remains loss-making and may need further funding before reaching profitability. Hospital adoption of new technologies can be slow, and revenue is weighted to the second half, adding forecast risk. Completion of the CME stake sale is not guaranteed.

Outlook

The 3.11% gain on 5 October 2026 suggests renewed confidence in Creo Medical Group Plc (LSE:CREO) as its revenue accelerates and costs fall. The second half will be crucial in proving that its growth guidance is achievable.